Welcome.
Are you a healthcare professional?

This website contains promotional information for Chiesi's respiratory products, and is intended solely for UK healthcare professionals. Please confirm below, or go back to the home page.

UK-RES-2101606 August 2021

You are now leaving Chiesi's website

By clicking this link, you will be taken to a website that is not owned or controlled by Chiesi. Chiesi is not responsible for the content provided on that site.

Continue
Go back

UK-RES-2101574 August 2021

INTENDED FOR UK HEALTHCARE PROFESSIONALS ONLY

The Fostair Family

The only extrafine formulation ICS/LABA combination available in a range of devices and strengths1–5

Designed to reach the large and small airways1–4,6

2 devices, 2 strengths, 2 indications1–4

  • Fostair 100/6 is indicated for adult asthma and COPD (FEV1 <50% predicted normal)1,3
  • Fostair 100/6 can also be used for Maintenance and Reliever Therapy (MART) for asthma in adults1,3
  • Fostair 200/6 is indicated for asthma in adults2,4

The only ICS/LABA fixed-dose combination licensed in asthma and COPD in both pressurised metered dose inhalers (pMDI) and dry powder inhalers (DPI).1,3

Fostair is indicated in the regular treatment of asthma in adults where use of a combination product (inhaled corticosteroid and long-acting β2-agonist) is appropriate: patients not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short-acting β2-agonist or patients already adequately controlled on both inhaled corticosteroids and long-acting β2-agonist.1-4

Fostair MART (100/6 ONLY) should especially be considered for patients with not fully controlled asthma and in need of reliever medication, patients with asthma exacerbations in the past requiring medical intervention.1,3

Fostair 100/6 is indicated for symptomatic treatment of patients with severe COPD (FEV1 <50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators.1,3

Fostair® NEXThaler and pMDI device images for 100/6 & 200/6
Indications
Fostair® NEXThaler and pMDI devices 100/6

Fostair 100/61,3

Available in both pMDI and NEXThaler DPI

  • Adult asthma
  • Maintenance and Reliever Therapy (MART)
  • COPD (FEV1 <50% predicted normal)
Fostair® NEXThaler and pMDI devices 200/6

Fostair 200/62,4

Available in both pMDI and NEXThaler DPI

  • Adult asthma
For additional information to share with your patients who have been prescribed Fostair NEXThaler or Fostair pMDI please visit our Fostair NEXThaler patient and carer site or Fostair pMDI patient and carer site.

Click here for Fostair® (beclometasone/formoterol) Prescribing Information.

COPD: chronic obstructive pulmonary disease; DPI: dry powder inhaler; FEV1: forced expiratory volume in 1 second; ICS: inhaled corticosteroid; LABA: long-acting β2-agonist; MART: maintenance and reliever therapy; pMDI: pressurised metered dose inhaler.

References:
1. Fostair NEXThaler 100/6 Summary of Product Characteristics. Chiesi Limited.
2. Fostair NEXThaler 200/6 Summary of Product Characteristics. Chiesi Limited.
3. Fostair pMDI 100/6 Summary of Product Characteristics. Chiesi Limited.
4. Fostair pMDI 200/6 Summary of Product Characteristics. Chiesi Limited.
5. MIMS online. 2021. Available at: https://www.mims.co.uk/.
6. Singh D. Tuberc Respir Dis. 2017; 80: 317–324.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Chiesi Ltd on 0800 0092329 (UK), 1800 817459 (IE) PV.UK@Chiesi.com.